Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)
  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling.
 
DeviceIMX TACROLIMUS II ASSAY
Generic NameENZYME IMMUNOASSAY, TRACROLIMUS
Regulation Number862.1678
ApplicantAbbott Laboratories
200 ABBOTT PARK RD.
ABBOTT PARK, IL 60064
PMA NumberP970007
Date Received02/18/1997
Decision Date08/26/1997
Reclassified Date 10/16/2002
Product Code MLM 
Docket Number 97M-0520
Notice Date 01/06/1998
Advisory Committee Toxicology
Expedited Review Granted? Yes
Combination ProductNo
RecallsCDRH Recalls
Approval Order Statement  
Approval for the IMx(R) Tacrolimus II Assay. This device is indicated for use as an in-vitro reagent sytemf or the quantitative determination of tacrolimus and some metabolites in human whole blood as an aid in the management of liver allograft patients receiving tacrolimus therapy.
Supplements:  S001 S002 S003 S004 
-
-